A neutrophil cell membrane-biomimetic nanoplatform based on l-arginine nanoparticles for early osteoarthritis diagnosis and nitric oxide therapy. Issue 32 (27th July 2022)

• Record Type: Journal Article
• Authors: Yu, Qianqian; Huang, Yuqin; Chen, Xu; Chen, Yutong; Zhu, Xufeng; Liu, Yanan; Liu, Jie
• Is Part Of: Nanoscale. Volume 14:Issue 32(2022)
• Page Start: 11619
• Page End: 11634
• Publication Date: 2022-07-27
• Subjects: Nanoscience -- Periodicals; Nanotechnology -- Periodicals; 620.505
• DOI: 10.1039/d2nr02601e
• Languages: English
• ISSNs: 2040-3364

Abstract

Abstract : Neutrophile-cell-membrane-based biomimetic nanoparticles were developed for the targeted recognition of inflamed osteoarthritis, dual-modal imaging diagnosis, and NO gas therapy. Abstract : Osteoarthritis (OA) is a common debilitating disease affecting articular joints for which no effective disease-modifying early diagnosis or medical therapy tools are currently available. The inefficient delivery of drugs into inflamed chondrocytes has restricted the development of anti-OA medication. Evidence has shown that inflammatory neutrophils possess the property of targeting inflammation via inflammatory tissue recruiting. Herein, we report neutrophil-cell-membrane-based biomimetic nanoparticles (NM-LANPs@Ru) as an OA theranostic nanoplatform; they act as a NO delivery system, coating neutrophil cell membrane onto the surface of self-assembled PEGylated l -arginine nanoparticles (LANPs) to act as a NO donor and loading a Ru complex to act as a ROS inducer. NM-LANPs@Ru demonstrated the specific targeting of inflamed OA with low toxicity, good NO release, and excellent fluorescence/photoacoustic (FL/PA) imaging properties. We showed that NM-LANPs@Ru exhibited enhanced cellular association in inflamed chondrocyte cells (C28/I2), much higher than NO release from ROS oxidized LA, and it improved the inhibition of the apoptosis of inflamed C28/I2 cells compared with control treatments. In vivo studies demonstrated that NM-LANPs@Ru effectively targeted inflamed OA, based on real-time dual-modal FL/PA imaging, eventually exhibiting its excellent anti-inflammatory activity. Our study may provide a new approach for the early diagnosis and treatment of osteoarthritis using a neutrophil-cell-membrane-based biomimetic nanoplatform for NO or drug delivery.